Exenatide Implant not checked

Vivani Medical, Inc · NPM115/NPM119

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.”In the company’s words, NCT05670379 on ClinicalTrials.gov
Tested for
Overweight and Obesity, Type2diabetes
Main trialPhase 1
“The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.”In the company’s words, NCT05670379 on ClinicalTrials.gov
Other names
NPM115/NPM119
Copy of
Bydureon Bcise (Astrazeneca AB)Tested side by side with the original in NCT05670379

Other drugs for Overweight and Obesity

All 167 drugs for Overweight and Obesity

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 21 Aug 2025 Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Exenatide Implant

Following is part of Solo: you see every change to Exenatide Implant the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in